A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

• Have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) in any order during the course oftreatment for multiple myeloma or have disease that is refractory to both a PI andan IMiD

• Evidence of a response (partial response [PR] or better based on investigator'sdetermination of response by International Myeloma Working Group [IMWG] criteria) toat least 1 prior treatment regimen

• Documented measurable disease for multiple myeloma at screening as defined inprotocol

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

• Contraceptive use by men or women should be consistent with local regulationsregarding the use of contraceptive methods for participants participating inclinical studies

Exclusion Criteria:

• Received any of the following prescribed medications or therapies in the past:Anti-CD38 antibody, including daratumumab, and/or Anti-PD-1 (programmed death-1) andanti-PD-L1 (programmed death-ligand 1) antibodies

• Plans to undergo a stem cell transplant prior to progression of disease on thisstudy (these participants should not be enrolled to reduce disease burden prior totransplant)

• History of malignancy (other than multiple myeloma) within 2 years prior to firstadministration of study drug (exceptions are squamous and basal cell carcinomas ofthe skin and carcinoma in situ of the cervix, or malignancy that in the opinion ofthe investigator, with concurrence with the sponsor's medical monitor, is consideredcured with minimal risk of recurrence within 3 years)

• Clinical signs of meningeal involvement of multiple myeloma

• Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volumein 1 second (FEV1) <50% of predicted normal or known moderate or severe persistentasthma within the past 2 years, or uncontrolled asthma of any classification